Nanomix Corp. (NNMX)

[Trend-Setter]

Nanomix is the leader in the development of mobile point-of-care (POC) diagnostics, with a handheld testing platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical for clinical decision-making and improved patient care.

Today’s model of centralized healthcare services works for patients who can access hospitals and whose conditions can be adequately addressed in hours or days rather than minutes. But many medical decisions require faster intervention. Advances in mobile communications and point-of-care platforms are driving a decentralization of disease diagnosis, improving our ability to treat patients faster, even without a visit to the hospital.

Our products are designed to improve healthcare delivery by bringing the most important diagnostic information to the point of initial patient interaction, whether in the hospital or in settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more. This kind of testing supports treating patients where they are as well as choosing the right treatment faster.

Nanomix was founded in 2000 by UC Berkeley professors and award-winning physicists at Lawrence Berkeley National Laboratory, Marvin L. Cohen and Alex Zettl. Today, our company is poised to become the premier provider of the next generation of rapid point-of-care diagnostics. The POC testing market is currently valued at approximately $20 billion.

Our first assay addresses the critical need to provide more comprehensive information to clinicians faster to aid in the diagnosis of sepsis and other critical infections. We are developing a deep pipeline of other high-value tests where the rapid availability of high-quality diagnostic information can improve patient outcomes, including:

>>> Acute kidney injury
>>> SARS-CoV-2 antigen and antibody tests for COVID-19
>>> Rapid multi-application cardiac testing
>>> Stroke
>>> Traumatic brain injury
In 2017, Nanomix formed a collaboration with World Technology East 2, RedPharm Biotechnology Ltd, and associated entities in Hong Kong, China, and the European Community. Our partnership focuses on the use and deployment of Nanomix products and technology throughout Asia for human applications and worldwide veterinary applications in farm animal, companion animal, and wildlife management and control.

https://nano.com/nanomix.php